Profile data is unavailable for this security.
About the company
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
- Revenue in USD (TTM)37.89m
- Net income in USD-12.13m
- Incorporated2017
- Employees44.00
- LocationEquillium Inc2223 Avenida de La Playa Ste 105LA JOLLA 92037-3217United StatesUSA
- Phone+1 (858) 412-5302
- Fax+1 (302) 636-5454
- Websitehttps://www.equilliumbio.com/home/default.aspx
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cara Therapeutics Inc | 16.94m | -122.54m | 14.87m | 55.00 | -- | 0.4989 | -- | 0.878 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Medicine Man Technologies Inc | -100.00bn | -100.00bn | 15.20m | 729.00 | -- | 0.2034 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -8.33 | -- | -9.85 | -- | 45.57 | -- | -15.71 | 0.2457 | -- | 0.6059 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
Talphera Inc | 651.00k | -14.31m | 15.63m | 15.00 | -- | 0.9571 | -- | 24.01 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
Ibio Inc | 50.00k | -17.13m | 16.99m | 26.00 | -- | 0.6749 | -- | 339.77 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
Pharmacyte Biotech Inc | 0.00 | -14.82m | 16.99m | 2.00 | -- | 0.5459 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
Aytu Biopharma Inc | 93.76m | -13.68m | 17.02m | 150.00 | -- | 0.5156 | -- | 0.1815 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
TherapeuticsMD Inc | 1.20m | -6.20m | 18.11m | 1.00 | -- | 0.6316 | -- | 15.10 | -0.58 | -0.6955 | 0.1103 | 2.49 | 0.0236 | -- | 0.4556 | 1,199,000.00 | -12.19 | -53.35 | -16.34 | -111.61 | 73.89 | 86.67 | -516.93 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
Polypid Ltd | 0.00 | -24.25m | 19.19m | 59.00 | -- | 2.69 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
KALA BIO Inc | 0.00 | -39.55m | 19.21m | 43.00 | -- | 2.88 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
Aptorum Group Ltd | 431.38k | -2.82m | 21.61m | 3.00 | -- | 0.8238 | -- | 50.10 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
Cumberland Pharmaceuticals, Inc. | 38.83m | -8.42m | 21.71m | 91.00 | -- | 0.7881 | -- | 0.5592 | -0.596 | -0.596 | 2.72 | 1.94 | 0.4542 | 0.8812 | 3.08 | 426,654.70 | -9.83 | -7.03 | -14.07 | -9.52 | 83.54 | 79.95 | -21.65 | -17.64 | 1.21 | -37.10 | 0.3717 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
Equillium Inc | 37.89m | -12.13m | 23.34m | 44.00 | -- | 1.11 | -- | 0.6159 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
Rapid Micro Biosystems Inc | 23.10m | -51.90m | 25.85m | 193.00 | -- | 0.2436 | -- | 1.12 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
Vyne Therapeutics Inc | 423.00k | -28.50m | 26.59m | 10.00 | -- | 0.3139 | -- | 62.85 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
Acasti Pharma Inc | 0.00 | -12.85m | 27.26m | 32.00 | -- | 0.4415 | -- | -- | -1.46 | -1.46 | 0.00 | 6.57 | 0.00 | -- | -- | -- | -16.86 | -31.68 | -17.45 | -33.95 | -- | -- | -- | -56,271.43 | -- | -6.18 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 31.82m | 1.00 | -- | 0.1776 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 836.12k | 2.37% |
Renaissance Technologies LLCas of 31 Mar 2024 | 209.20k | 0.59% |
Geode Capital Management LLCas of 31 Mar 2024 | 199.73k | 0.57% |
Adar1 Capital Management LLCas of 31 Mar 2024 | 198.78k | 0.56% |
Acadian Asset Management LLCas of 31 Mar 2024 | 108.69k | 0.31% |
Callan Capital LLCas of 31 Mar 2024 | 99.69k | 0.28% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 52.62k | 0.15% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 50.04k | 0.14% |
Jane Street Capital LLCas of 31 Mar 2024 | 41.76k | 0.12% |
American Century Investment Management, Inc.as of 31 Mar 2024 | 40.33k | 0.11% |